Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Short term Debt: 2010-2025

Historic Short term Debt for OptimizeRx (OPRX) over the last 7 years, with Q3 2025 value amounting to $3.3 million.

  • OptimizeRx's Short term Debt rose 6500.0% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 6500.0%. This contributed to the annual value of $2.0 million for FY2024, which is 0.0% changed from last year.
  • Latest data reveals that OptimizeRx reported Short term Debt of $3.3 million as of Q3 2025, which was up 6500.0% from $3.3 million recorded in Q2 2025.
  • OptimizeRx's Short term Debt's 5-year high stood at $3.5 million during Q1 2024, with a 5-year trough of $2.0 million in Q4 2023.
  • For the 3-year period, OptimizeRx's Short term Debt averaged around $2.8 million, with its median value being $3.3 million (2024).
  • Within the past 5 years, the most significant YoY rise in OptimizeRx's Short term Debt was 6500.0% (2025), while the steepest drop was 571.43% (2025).
  • Quarter analysis of 3 years shows OptimizeRx's Short term Debt stood at $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then surged by 65.0% to $3.3 million in 2025.
  • Its Short term Debt stands at $3.3 million for Q3 2025, versus $3.3 million for Q2 2025 and $3.3 million for Q1 2025.